Secukinumab in The Treatment of Psoriasis: An Update

Abstract

Biological drugs are pharmaceuticals manufactured using biotechnology methods that may target specific cytokines, cytokine receptors or surface molecules, and modulate the immunological response of the organism. Psoriasis is a common cutaneous disease in which biological drugs have been evaluated and widely accepted in clinical practice. Secukinumab is a monoclonal antibody targeting IL-17A which has been extensively researched in clinical trials and registered in treating moderate to severe plaque psoriasis. We performed a literature search in Pubmed database on the pharmacology of secukinumab and randomized clinical trials investigating its efficacy and safety in treating plaque psoriasis in comparison to placebo or biological drugs (etanercept, ustekinumab). The administration of secukinumab in psoriatic subjects resulted in subjective and objective disease parameters reduction while exhibiting high safety profile. Secukinumab is an effective drug with a favorable safety profile. It has already taken an important position in managing plaque psoriasis in clinical practice.

Cost‐effectiveness of secukinumab as first biologic treatment, compared with other biologics, for moderate to severe psoriasis in Germany

“…[13][14][15][16][17][18] Numerous clinical trials have shown that the proportion of patients achieving Psoriasis Area and Severity Index (PASI) 75 and PASI 90 response at week 12 was significantly higher in patients receiving secukinumab 300 mg compared to placebo (P < 0.001) 17,19,20 and etanercept (P < 0.001), 17 as well as compared to ustekinumab (P < 0.0001) at week 16 18 and at week 52. [13][14][15][16][17][18] Numerous clinical trials have shown that the proportion of patients achieving Psoriasis Area and Severity Index (PASI) 75 and PASI 90 response at week 12 was significantly higher in patients receiving secukinumab 300 mg compared to placebo (P < 0.001) 17,19,20 and etanercept (P < 0.001), 17 as well as compared to ustekinumab (P < 0.0001) at week 16 18 and at week 52.…”

“…Secukinumab, a fully human monoclonal antibody that selectively neutralizes IL-17A, has demonstrated superior and sustained efficacy in the treatment of moderate to severe psoriasis. [13][14][15][16][17][18] Numerous clinical trials have shown that the proportion of patients achieving Psoriasis Area and Severity Index (PASI) 75 and PASI 90 response at week 12 was significantly higher in patients receiving secukinumab 300 mg compared to placebo (P < 0.001) 17,19,20 and etanercept (P < 0.001), 17 as well as compared to ustekinumab (P < 0.0001) at week 16 18 and at week 52. 21 Secukinumab is approved in Germany since 2015 for moderate to severe psoriasis, psoriatic arthritis and ankylosing spondylitis.…”

Secukinumab treatment in psoriatic patients: Italian experiences

“…The activation of these cells promotes the release of inflammatory cytokines and induces pathological processes in several tissues: vessel activation, matrix destruction, cartilage damage, and bone erosion (5,6). Secukinumab is a human IgG1 monoclonal antibody that selectively binds and neutralizes IL-17A (7,8). Its efficacy in chronic plaque psoriasis has been demonstrated by several clinical trials and secukinumab has recently been approved for the treatment of psoriatic arthritis in adults, alone or in association with methotrexate (MTX) when the response to previous DMARDs is inadequate (7).…”

“…Secukinumab is a human IgG1 monoclonal antibody that selectively binds and neutralizes IL-17A (7,8). Its efficacy in chronic plaque psoriasis has been demonstrated by several clinical trials and secukinumab has recently been approved for the treatment of psoriatic arthritis in adults, alone or in association with methotrexate (MTX) when the response to previous DMARDs is inadequate (7). Articles published in this supplement report clinical experiences in the use of secukinumab in different psoriasis variants.…”

Efficacy and Safety of BCD-085, a Novel Interleukin-17 Inhibitor. Results of Phase II Clinical Trial in Patients with Moderate-to-Severe Plaque Psoriasis

“…В 2016 г. в России был зарегистрирован первый биологический препарат, направленный на блокаду ИЛ-17,секукинумаб производства компании Новартис Фарма АГ (Швейцария), который представляет собой полностью человеческое антитело (IgG1), селективно связывающее и нейтрализующее ИЛ-17А [12,16]. По результатам регистрационных исследований III фазы секукинумаба у пациентов со среднетяжелым и тяжелым вульгарным псориазом порядка 80% пациентов достигли PASI 75 (первичной конечной точки) к 12-й неделе лечения, также препарат продемонстрировал превосходство над этанерцептом и устекинумабом [12,24]. С 2011 г. в российской биотехнологической компании «БИОКАД» велась разработка собственного оригинального моноклонального антитела против ИЛ-17.…”